Immuron in second US gut health trial

A second new drug from biotechnology company Immuron is to undergo human trials in the United States following a decision by the Food and Drug Administration that allows trials to proceed. The Melbourne company told investors the US Naval Medical Research Centre (NMRC) had received approval to trial the drug targeting Campylobacter and Enterotoxigenic Escherichia…

Hopes for the federal budget to revive Australia’s manufacturing sector

The government should prioritise building sovereign capability, argues Martin Ripple ahead of Tuesday night’s federal budget. As we are awaiting the budget announcement, it is crucial that the federal government addresses the issue of sovereign capability in the country’s manufacturing industry. Australia has the highest dependency on manufactured imports and the lowest level of manufacturing…

Defence partnering for success – Ukraine brings cybersecurity into focus

@AuManufactruring’s sponsored series reporting BAE Systems Australia’s Partnering for success defence industry supplier event, concludes today, with a focus on cyber security. By Nicholas Way The tragic war in Ukraine has been a catalyst for serious investment in cybersecurity by defence organisations globally, and Australia is no exception. That’s the view of Tony Howell, Global…

Sicona Battery Technologies moves on graphite to graphene process

Start up business Sicona Battery Technologies has purchased a world-first, scalable, edge-functionalised graphene production method from researchers at the ARC Centre of Excellence for Electromaterials and ANFF-Materials. As part of the deal, Sicona signed a two-year research agreement with Australian National Fabrication Facility (ANFF) researchers to scale up the EFG fabrication process for commercial production…